©2024 Stanford Medicine
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
Not Recruiting
Trial ID: NCT04213261
Purpose
The purpose of this study is to determine whether administration of FCX-007 in addition to
standard of care improves wound healing as compared to standard of care alone (control) in
children, adolescents, and adults with Recessive Dystrophic Epidermolysis Bullosa.
Funding Source - FDA OOPD
Official Title
A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa
Stanford Investigator(s)
M. Peter Marinkovich, MD
Associate Professor of Dermatology
Eligibility
Key Inclusion Criteria:
- Male or female ≥2 years of age at the Screening visit.
- Clinical diagnosis of RDEB with confirmation of COL7A1 genetic mutation.
Key Exclusion Criteria:
- Medical instability limiting ability to travel to the investigative site.
- Active infection with human immunodeficiency virus, hepatitis B or hepatitis C.
- The presence of COL7 antibodies.
- Evidence of systemic infection.
- Evidence or history of squamous cell carcinoma at the site to be injected.
- Evidence of or history of metastatic squamous cell carcinoma.
- Known allergy to any of the constituents of the product.
- Female who is pregnant or breastfeeding.
- Receipt of a chemical or biological intervention for the specific treatment of RDEB in
the past three (3) months prior to screening or anticipated/planned during the
screening and treatment period for this study.
Intervention(s):
biological: FCX-007 (dabocemagene autoficel; see below for FCX-007 description)
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kunju J Sridhar, PhD
650-721-4902